South Korea’s Hanmi Opens Global Trials Of Monthly Dose GLP-1 Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Hanmi hopes to differentiate its type 2 diabetes Byetta biosimilar with once-a-month administration.